[en] Angina is chest pain induced by ischemia of the heart muscle, generally due to obstruction or spasm of the coronary arteries. People that suffer from average to severe cases of angina have an increased percentage of death before the age of 55, usually around 60%. Therefore, prevention of major complications, optimizing diagnosis, prognosis and therapeutics are of primary importance. The main objective of this study was to uncover biomarkers by comparing serum protein profiles of patients suffering from stable or unstable angina and controls. We identified by non-targeted proteomic approach and confirmed by the means of independent techniques, the differential expression of several proteins indicating significantly increased vascular inflammation response, disturbance in the lipid metabolism and in atherogenic plaques stability.
Disciplines :
Biochemistry, biophysics & molecular biology Cardiovascular & respiratory systems
Author, co-author :
Fillet, Marianne ; Université de Liège - ULiège > Département de pharmacie > Analyse des médicaments
Deroyer, Céline ; Université de Liège - ULiège > Département de pharmacie > Analyse des médicaments
COBRAIVILLE, Gaël ; Université de Liège - ULiège > Département de pharmacie > Analyse des médicaments
LE GOFF, Caroline ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Chapelle, Jean-Paul ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
Pierard, Luc ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Kolh, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et path.
Merville, Marie-Paule ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Language :
English
Title :
Identification of protein biomarkers associated with cardiac ischemia by a proteomic approach.
Publication date :
2013
Journal title :
Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
Alexanian R, Barlogie B, Fritsche H. (1985). Beta 2 microglobulin in multiple myoloma. Amm J Hematol 20:345-51.
Altwegg LA, Neidhart M, Hersberger M, et al. (2007). Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: A novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 28:941-8.
Baumann M, Schmaderer C, Burkhardt K, et al. (2011). MRP8/14 is associated with systemic inflammation in stable coronary atherosclerosis in men. Eur J Clin Invest 41:1261-7.
Birjmohun RS, Dallinga-Thie G, Kuivenhoven JA, et al. (2007). Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation 116:2029-35.
Bisoendial RJ, Boekholdt S, Vergeer M, et al. (2010). C-reactive protein is a mediator of cardiovascular disease. Eur Heart J 31:2087-91.
Butterfield AM, Luan P, Witcher DR, et al. (2010). A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin Chem 56:1725-32.
Cooke JP, Wilson AM. (2010). Biomarkers of peripheral arterial disease. J Am Coll Cardiol 55:2017-23.
Danesh J, Wheeler JG, Hircshfield GM, et al. (2004). C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387-97.
de Seny D, Fillet M, Meuwis MA, et al. (2005). Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum 52:3801-12.
de Seny D, Sharif M, Fillet M, et al. (2011). Discovery and biochemical characterisation of four novel biomarkers for osteoarthritis. Ann Rheum Dis 70:1144-52.
Ganz T. (2011). Hepcidin and iron regulation, 10 years later. Blood 117: 4425-33.
Ganz T, Olbina G, Girelli D, et al. (2008). Immunoassay for human serum hepcidin. Blood 112:4292-7.
Geurts P, Fillet M, de Seny D, et al. (2005). Proteomic mass spectra classification using decision tree based ensemble methods. Bioinformatics 21:3138-45.
Harb TS, Zareba W, Moss AJ, et al. (2002). Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. Am J Cardiol 89: 216-21.
Jankowska EA, Malyszko J, Ardehali H, et al. (2013). Iron status in patients with chronic heart failure. Eur Heart J 34:827-34.
Johnson BD, Kip KE, Marroquin OC, et al. (2004). Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109: 726-32.
Julve J, Escola-Gil JC, Rotllan N, et al. (2010). Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. Arterioscler Thromb Vasc Biol 30:232-8.
Kaplan KL, Owen J. (1981). Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 57: 199-202.
Kouz R, Rheaume E, Berry C, et al. (2011). Circulating VEGF concentrations are independently predictive of coronary artery disease severity measured by quantitative coronary angiography in patients with stable angina. J Am Coll Cardiol 57:E1464. doi:10.1016/S0735- 1097(11)61464-2.
Labarrere CA, Zaloga GP. (2004). C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 117: 499-507.
Liao H, Wu J, Kuhn E, et al. (2004). Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum 50: 3792-803.
Mair J. (2002). Role of cardiac natriuretic peptide testing in heart failure. Clinical chemistry 48:977-8.
Marcovina SM, Crea F, Davignon C, et al. (2007). Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: A road to integration of complementary diagnostic tools. J Intern Med 261:214-34.
Meuwis MA, Fillet M, Geurts P, et al. (2007). Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharm 73:1422-33.
Mills EJ, Wu P, Chong G, et al. (2011). Efficacy and safety of statin treatment for cardiovascular disease: A network meta-analysis of 170 255 patients from 76 randomized trials. QJM 104:109-24.
Morrow DA, Braunwald E. (2003). Future of biomarkers in acute coronary syndromes: Moving toward a multimarker strategy. Circulation 108:250-2.
Morrow DA, Rifai N, Antman EM, et al. (2000). Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol 35:358-62.
Murao SM. (1994). Two calcium-binding protein, MRP8 and MRP14: A protein complex associated with neutrophil and monocytes activation. Acta Histochem Cytochem 27:107-16.
Ogawa, H, Yasue H, Oshima S, et al. (1989). Circadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation 80:1617-26.
Park JP, Park MK, Yun JW. (2011). Proteomic biomarkers for diagnosis in acute myocardial infarction. Biomarkers 16:1-11.
Panteghini M, Bonetti G, Pagani F, et al. (2005). Measurement of troponin I 48 h after admission as a tool to rule out impaired left ventricular function in patients with a first myocardial infarction. Clin Chem Lab Med 43:848-54.
Perna ER, Macin SM, Canella JP, et al. (2004). Ongoing myocardial injury in stable severe heart failure: Value of cardiac troponin T monitoring for high-risk patient identification. Circulation 110: 2376-82.
Peronnet E, Becquart L, Martinez J, et al. (2007). Isoelectric point determination of cardiac troponin I forms present in plasma from patients with myocardial infarction. Clin Chim Acta 377:243-7.
Pinet F, Beseme O, Cieniewski-Bernard C, et al. (2008). Predicting left ventricular remodeling after a first myocardial infarction by plasma proteome analysis. Proteomics 8:1798-808.
Sabatine MS, Morrow DA, de Lemos JA, et al. (2002). Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105:1760-3.
Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. (2004). Lymphatic vasculature: Development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25:387-95.
Simonis G, Mueller K, Schwarz P, et al. (2010). The iron-regulatory peptide hepcidin is upregulated in the ischemic and in the remote myocardium after myocardial infarction. Peptides 31:1786-90.
Song C, Shen Y, Yamen E, et al. (2009). Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes. Atherosclerosis 202:596-604.
Srinivasan SR, Berenson GS. (1995). Serum apolipoproteins A-I and B as markers of coronary artery disease risk in early life: The Bogalusa Heart Study. Clin Chem 41:159-64.
Sullivan JL. (2007). Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood) 232:1014-20.
Surendran RP, Visser ME, Heemelaar S, et al. (2012). Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 272:185-96.
Syväranta S, Helske S, Lappalainen J, et al. (2012). Lymphangiogenesis in aortic valve stenosis-novel regulatory roles for valvular myofibroblasts and mast cells. Atherosclerosis 221:366-74.
Testa U, Pannitteri G, Condorelli GL. (2008). Vascular endothelial growth factors in cardiovascular medicine. J Cardiovasc Med (Hagerstown) 9:1190-221.
Tousoulis D, Antoniades C, Stefanadis C. (2007). Assessing inflammatory status in cardiovascular disease. Heart 93:1001-7.
Vogl T, Tenbrock K, Ludwig S, et al. (2007). Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13:1042-9.
Walldius G, Jungner I. (2004). Apolipoprotein B and apolipoprotein A-I: Risk indicators of coronary heart disease and targets for lipidmodifying therapy. J Intern Med 255:188-205.
Walldius G, Jungner I. (2005). Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipidlowering therapy. Eur Heart J 26:210-12.
Wilson AM, Kimura E, Harada RK, et al. (2007). Beta2-microglobulin as a biomarker in peripheral arterial disease: Proteomic profiling and clinical studies. Circulation 116:1396-403.
Wiviott SD, de Lemos JA, Morrow A. (2004). Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. Clin Chim Acta 346:119-28.
Zakynthinos E, Pappa N. (2009). Inflammatory biomarkers in coronary artery disease. Journal of cardiology 53:317-33.
